Oncology

Back to articles

Novel approaches to adjuvant therapies for Stage III or IV melanoma prove successful

KEY POINT

Two pivotal trials published in the New England Journal of Medicine show that adjuvant therapy with dabrafenib (Tafinlar—Novartis) plus trametinib (Mekinist—Novartis) for patients with resected, Stage III melanoma with the BRAF V600 mutation resulted in a statistically significant improvement in relapse-free survival compared with placebo; and use of adjuvant nivolumab (Opdivo—Bristol-Myers Squibb) for patients with resected, Stage III or IV melanoma resulted in a statistically significantly better 12-month rate of recurrence-free survival compared with use of ipilimumab (Yervoy—Bristol-Myers Squibb).

SOURCES

Long GV, et al. Adjuvant dabrafenib plus trametinib in Stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813–23.

Weber J, et al. Adjuvant nivolumab versus ipilimumab in resected Stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–35.

Schuchter LM. Adjuvant melanoma therapy—head-spinning progress. N Engl J Med. 2017;377(19):1888–90.